Cancer Research AACR Legacy  Sign up for Cancer Research eTOC's
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kurban, G.
Right arrow Articles by Pause, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kurban, G.
Right arrow Articles by Pause, A.
[Cancer Research 66, 1313-1319, February 1, 2006]
© 2006 American Association for Cancer Research


Molecular Biology, Pathobiology, and Genetics

Characterization of a von Hippel Lindau Pathway Involved in Extracellular Matrix Remodeling, Cell Invasion, and Angiogenesis

Ghada Kurban1, Valérie Hudon1, Eric Duplan1, Michael Ohh2 and Arnim Pause1

1 McGill Cancer Center and Department of Biochemistry, McGill University, Montreal, Quebec and 2 Department of Laboratory Medicine and Pathobiology, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada

Requests for reprints: Arnim Pause, McGill Cancer Center and Department of Biochemistry, McGill University, 3655 Promenade Sir William Osler, Room 716, Montreal, Quebec, H3G 1Y6. Phone: 514-398-1521; Fax: 514-398-6769; E-mail: arnim.pause{at}mcgill.ca.

Inactivation of the von Hippel-Lindau (VHL) tumor suppressor gene results in highly vascularized tumors, making the VHL tumor syndrome an ideal system to study the mechanisms of angiogenesis. VHL operates along two pathways with the first involving hypoxia-inducible factor-{alpha} degradation and down-regulation of its proangiogenic target genes vascular endothelial growth factor and platelet-derived growth factor-ß, and the second pathway promoting extracellular matrix (ECM) assembly. Secretion of proangiogenic factors was shown to be a primary inducer of angiogenesis. Here, we show that loss of ECM assembly correlates with tumor angiogenesis in VHL disease. Upon inactivation of the VHL-ECM assembly pathway, we observe tumors that are highly vascularized, have a disrupted ECM, and show increased matrix metalloproteinase-2 activity. Loss of the VHL pathway leading to hypoxia-inducible factor-{alpha} degradation results in tumors with increased vascular endothelial growth factor levels but with surprisingly low microvessel density, a tightly assembled ECM and low invasive ability. We conclude that loss of ECM integrity could promote and maintain tumor angiogenesis by providing a route for blood vessels to infiltrate tumors. (Cancer Res 2006; 66(3): 1313-9)




This article has been cited by other articles:


Home page
Mol Cancer ResHome page
A. H.T. Nguyen, M. Beland, Y. Gaitan, and M. Bouchard
Calcineurin A-Binding Protein, a Novel Modulator of the Calcineurin-Nuclear Factor of Activated T-Cell Signaling Pathway, Is Overexpressed in Wilms' Tumors and Promotes Cell Migration
Mol. Cancer Res., June 1, 2009; 7(6): 821 - 831.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
K. Knauth, E. Cartwright, S. Freund, M. Bycroft, and A. Buchberger
VHL Mutations Linked to Type 2C von Hippel-Lindau Disease Cause Extensive Structural Perturbations in pVHL
J. Biol. Chem., April 17, 2009; 284(16): 10514 - 10522.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
I. Wacker, M. Sachs, K. Knaup, M. Wiesener, J. Weiske, O. Huber, Z. Akcetin, and J. Behrens
Key Role for Activin B in Cellular Transformation after Loss of the von Hippel-Lindau Tumor Suppressor
Mol. Cell. Biol., April 1, 2009; 29(7): 1707 - 1718.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
T. A. Sutton, J. Wilkinson, H. E. Mang, N. L. Knipe, Z. Plotkin, M. Hosein, K. Zak, J. Wittenborn, and P. C. Dagher
p53 regulates renal expression of HIF-1{alpha} and pVHL under physiological conditions and after ischemia-reperfusion injury
Am J Physiol Renal Physiol, December 1, 2008; 295(6): F1666 - F1677.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
K. Kimura, M. Iwano, D. F. Higgins, Y. Yamaguchi, K. Nakatani, K. Harada, A. Kubo, Y. Akai, E. B. Rankin, E. G. Neilson, et al.
Stable expression of HIF-1{alpha} in tubular epithelial cells promotes interstitial fibrosis
Am J Physiol Renal Physiol, October 1, 2008; 295(4): F1023 - F1029.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M. Feijoo-Cuaresma, F. Mendez, A. Maqueda, M. A. Esteban, S. Naranjo-Suarez, M. C. Castellanos, M. H. del Cerro, S. N. Vazquez, A. Garcia-Pardo, M. O. Landazuri, et al.
Inadequate Activation of the GTPase RhoA Contributes to the Lack of Fibronectin Matrix Assembly in von Hippel-Lindau Protein-defective Renal Cancer Cells
J. Biol. Chem., September 5, 2008; 283(36): 24982 - 24990.
[Abstract] [Full Text] [PDF]


Home page
J. Cell Sci.Home page
F. Shi and J. Sottile
Caveolin-1-dependent {beta}1 integrin endocytosis is a critical regulator of fibronectin turnover
J. Cell Sci., July 15, 2008; 121(14): 2360 - 2371.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
N. D. Kirkpatrick, M. A. Brewer, and U. Utzinger
Endogenous Optical Biomarkers of Ovarian Cancer Evaluated with Multiphoton Microscopy
Cancer Epidemiol. Biomarkers Prev., October 1, 2007; 16(10): 2048 - 2057.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
V. Dormoy-Raclet, I. Menard, E. Clair, G. Kurban, R. Mazroui, S. Di Marco, C. von Roretz, A. Pause, and I.-E. Gallouzi
The RNA-Binding Protein HuR Promotes Cell Migration and Cell Invasion by Stabilizing the {beta}-actin mRNA in a U-Rich-Element-Dependent Manner
Mol. Cell. Biol., August 1, 2007; 27(15): 5365 - 5380.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
A. Grosfeld, I. P. Stolze, M. E. Cockman, C. W. Pugh, M. Edelmann, B. Kessler, A. N. Bullock, P. J. Ratcliffe, and N. Masson
Interaction of Hydroxylated Collagen IV with the von Hippel-Lindau Tumor Suppressor
J. Biol. Chem., May 4, 2007; 282(18): 13264 - 13269.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
W. G. Kaelin Jr.
The von Hippel-Lindau Tumor Suppressor Protein and Clear Cell Renal Carcinoma
Clin. Cancer Res., January 15, 2007; 13(2): 680s - 684s.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
A. J. Evans, R. C. Russell, O. Roche, T. N. Burry, J. E. Fish, V. W. K. Chow, W. Y. Kim, A. Saravanan, M. A. Maynard, M. L. Gervais, et al.
VHL Promotes E2 Box-Dependent E-Cadherin Transcription by HIF-Mediated Regulation of SIP1 and Snail
Mol. Cell. Biol., January 1, 2007; 27(1): 157 - 169.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
A. Franovic, I. Robert, K. Smith, G. Kurban, A. Pause, L. Gunaratnam, and S. Lee
Multiple Acquired Renal Carcinoma Tumor Capabilities Abolished upon Silencing of ADAM17
Cancer Res., August 15, 2006; 66(16): 8083 - 8090.
[Abstract] [Full Text] [PDF]


Home page
JNCI J Natl Cancer InstHome page
A. Albini and U. Pfeffer
A new tumor suppressor gene: invasion, metastasis, and angiogenesis as potential key targets.
J Natl Cancer Inst, June 21, 2006; 98(12): 800 - 801.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2006 by the American Association for Cancer Research.